Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

News

March 25, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” continue reading »

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

News

March 20, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.” continue reading »

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

News

March 19, 2024
PRESS RELEASE: On March 15, 2024, a new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., in Oncotarget, entitled, “From osimertinib to preemptive combinations.” continue reading »

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation

News

March 18, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.” continue reading »

Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy

Oncotarget

March 14, 2024
In this study, researchers investigated the antitumor effects of Sacituzumab govitecan in combination with platinum-based chemotherapy. continue reading »